1e409782-57e3-42ab-8952-678a4cdb6b2f
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 42
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.280
- MYC_TARGETS_V2+0.250
- PEROXISOME+0.220
- ESTROGEN_RESPONSE_LATE+0.200
- MITOTIC_SPINDLE+0.190
- CHOLESTEROL_HOMEOSTASIS+0.180
- FATTY_ACID_METABOLISM+0.160
- HEME_METABOLISM+0.140
- ADIPOGENESIS+0.110
- ESTROGEN_RESPONSE_EARLY+0.110
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.600
- INTERFERON_GAMMA_RESPONSE-0.510
- INTERFERON_ALPHA_RESPONSE-0.500
- ALLOGRAFT_REJECTION-0.480
- IL6_JAK_STAT3_SIGNALING-0.470
- INFLAMMATORY_RESPONSE-0.430
- ANGIOGENESIS-0.370
- COMPLEMENT-0.350
- HEDGEHOG_SIGNALING-0.350
- TNFA_SIGNALING_VIA_NFKB-0.330
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CV-A6JY-01A-11R-A31N-07 | — | — | 0.847 |
| 2 | ERR2278863 | — | — | 0.839 |
| 3 | 68fda9a5-c6eb-4445-91f7-bd0078080b9d | — | — | 0.838 |
| 4 | aMVAC.P_016_TURBT_S236 | — | — | 0.832 |
| 5 | aMVAC.P_001_TURBT_S217 | — | — | 0.831 |
| 6 | TCGA-CN-6988-01A-11R-1915-07 | — | — | 0.830 |
| 7 | SRR8943016 | — | — | 0.829 |
| 8 | TCGA-DK-AA6P-01A-11R-A39I-07 | — | — | 0.826 |
| 9 | TCGA-B6-A0IC-01A-11R-A034-07 | — | B | 0.825 |
| 10 | SRR29022828 | — | B | 0.822 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.280 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.250 | Idelalisib | — uncovered |
| PEROXISOME | 0.220 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.200 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.190 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.180 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.160 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.140 | Temsirolimus | — uncovered |
| ADIPOGENESIS | 0.110 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.110 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.080 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.070 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.060 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.050 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.050 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.030 | Remibrutinib | — uncovered |